Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News

Price

$0.285

Movement

0.005 (-1.72%)

as at 22 May 10:35am (20 mins delayed)

52 Week Range

$0.275 - $0.614

 
1 Year Return

-50.39%

Recce Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $75.98 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 262.00 million
Earnings per share -0.091
Dividend per share N/A
Year To Date Return -38.59%
Earnings Yield N/A
Franking -
Share Price

$0.285

Day Change

0.005 (-1.72%)

52 Week Range

$0.275 - $0.614

Yesterday's Close

$0.29

Today's Open

$0.285

Days Range

$0.285 - $0.285

Volume

5,236

Avg. Volume (1 month)

151,523

Turnover

$1,492

as at 22 May 10:35am

Recce Pharmaceuticals Ltd (ASX: RCE)
Latest News

A drawing of a rocket follows a chart up, indicating share price lift
Share Gainers

Why the Recce Pharmaceuticals (ASX:REE) share price is storming higher today

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is on the move on Tuesday following the release of an update on…

Read more »

a doctor looking up at question marks
Healthcare Shares

Why is the Recce (ASX:RCE) share price falling today?

The Recce (ASX: RCE) share price is down 1.85% today after the company released its quarterly activities report.

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Recce (ASX:RCE) share price surges 6% on clinical trial registration

The Recce Pharmaceuticals (ASX: RCE) share price is soaring today after the company announced positive progress on its Recce 327…

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Share Gainers

The Recce (ASX:RCE) share price is up 7% after its drug saved a human

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is up 7% after the company shared good news of the use…

Read more »

Share Gainers

Why EML, NextDC, Qantas, & Recce shares are racing higher

EML Payments Ltd (ASX:EML) and Qantas Airways Limited (ASX:QAN) shares are two of four racing notably higher on Wednesday...

Read more »

A woman with black afro hair and wearing a white t-shirt shrugs and purses her lips
Healthcare Shares

Why is the Recce (ASX:RCE) share price in the red today?

The Recce (ASX: RCE) share price is in the red today despite the company releasing positive data from its latest…

Read more »

A businessman in front of a computer with his head on his hand in disbelief, indicating poor IPO or share price performance
Share Fallers

Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is under pressure on Tuesday despite the release of a positive update...

Read more »

high share price
Share Gainers

Here's why the Recce (ASX:RCE) share price is racing higher today

Here's why the Recce Pharmaceuticals Ltd (ASX:RCE) share price is pushing higher on Monday morning...

Read more »

excited investor making fist at computer screen
Share Gainers

Why Novonix, Recce, Singular Health, & Starpharma shares are storming higher

Novonix Ltd (ASX:NVX) and Singular Health Group Ltd (ASX:SHG) shares are two of four storming notably higher on Friday...

Read more »

Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today
Share Gainers

Why the Recce Pharmaceuticals (ASX:RCE) share price is rocketing 10% higher

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is rocketing higher on Friday after a positive update on its COVID-19 studies...

Read more »

Share Gainers

Why a2 Milk, Air New Zealand, Mesoblast, & Recce shares are storming higher

A2 Milk Company Ltd (ASX:A2M) and Mesoblast limited (ASX:MSB) shares are two of four storming higher on Wednesday...

Read more »

Share Gainers

Recce (ASX:RCE) share price charges higher on COVID-19 update

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is pushing higher today after releasing an update on its COVID-19 studies...

Read more »

RCE ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
20th May 2025 2025-05-20T12:14:45 Change in substantial holdingYesNo12:14pm2142k
16th May 2025 2025-05-16T16:54:25 Change of Director's Interest NoticesYesNo4:54pm181.4M
16th May 2025 2025-05-16T09:58:42 Results of Entitlement OfferYesNo9:58am3271k
16th May 2025 2025-05-16T09:50:27 Application for quotation of securities - RCEYesNo9:50am616k
5th May 2025 2025-05-05T11:56:41 Canadian R&D Rebate ReceivedYesNo11:56am2208k
30th Apr 2025 2025-04-30T18:22:05 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo6:22pm9384k
30th Apr 2025 2025-04-30T17:28:45 Update - Proposed issue of securities - RCEYesNo5:28pm926k
30th Apr 2025 2025-04-30T17:28:25 Extension of Entitlement Offer Closing DateYesNo5:28pm2215k
28th Apr 2025 2025-04-28T09:09:35 Recce Enters into USA Department of Defense R&D AgreementYesNo9:09am3335k
23rd Apr 2025 2025-04-23T17:48:33 Ceasing to be a substantial holder from MQGYesNo5:48pm13155k

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibioticdrugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

RCE Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
21 May 2025 $0.29 $-0.01 -3.39% 66,615 $0.29 $0.29 $0.29
20 May 2025 $0.30 $0.01 3.45% 142,601 $0.29 $0.30 $0.28
19 May 2025 $0.29 $0.00 0.00% 62,478 $0.29 $0.29 $0.28
16 May 2025 $0.29 $-0.01 -3.39% 224,865 $0.29 $0.29 $0.29
15 May 2025 $0.30 $-0.01 -3.28% 162,935 $0.30 $0.30 $0.29
14 May 2025 $0.31 $0.01 3.39% 176,525 $0.29 $0.31 $0.28
13 May 2025 $0.30 $-0.01 -3.33% 107,786 $0.31 $0.31 $0.29
12 May 2025 $0.30 $0.02 7.14% 106,690 $0.31 $0.31 $0.29
09 May 2025 $0.28 $0.00 0.00% 190,906 $0.28 $0.29 $0.28
08 May 2025 $0.29 $-0.02 -6.56% 345,633 $0.31 $0.31 $0.28
07 May 2025 $0.31 $0.01 3.33% 74,141 $0.30 $0.31 $0.30
06 May 2025 $0.30 $0.01 3.39% 59,791 $0.30 $0.30 $0.30
05 May 2025 $0.30 $0.01 3.45% 531 $0.29 $0.30 $0.29
02 May 2025 $0.29 $0.00 0.00% 70,037 $0.29 $0.30 $0.29
01 May 2025 $0.29 $0.00 0.00% 24,364 $0.29 $0.29 $0.29
30 Apr 2025 $0.29 $0.00 0.00% 332,060 $0.29 $0.29 $0.28
29 Apr 2025 $0.29 $0.01 3.51% 46,939 $0.29 $0.29 $0.29
28 Apr 2025 $0.29 $-0.01 -3.45% 443,666 $0.29 $0.30 $0.29
24 Apr 2025 $0.29 $0.00 0.00% 92,674 $0.29 $0.29 $0.28
23 Apr 2025 $0.29 $0.01 3.57% 114,505 $0.29 $0.29 $0.28

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
16 May 2025 James Graham Issued 35,714 $9,999
Rights issue. As per announcement on 16-05-2025
16 May 2025 Alistair McKeough Issued 4,326 $1,211
Rights issue.
16 May 2025 Alan Dunton Issued 19,469 $5,451
Rights issue.
16 May 2025 Michele Dilizia Issued 17,857 $4,999
Rights issue.
16 May 2025 John Prendergast Issued 51,136 $14,318
Rights issue.
16 May 2025 Justin Ward Issued 50,240 $14,067
Rights issue.
14 Nov 2024 James Graham Issued 3,000,000 $732,000
Issue of options. Black Scholes option
valuation methodology, estimated value
14 Nov 2024 Alistair McKeough Issued 1,000,000 $244,000
Issue of options. Black Scholes option
valuation methodology, estimated value
14 Nov 2024 Alan Dunton Issued 2,250,000 $549,000
Issue of options. Black Scholes option
valuation methodology, estimated value
14 Nov 2024 Michele Dilizia Issued 1,600,000 $390,400
Issue of options. Black Scholes option
valuation methodology, estimated value
14 Nov 2024 John Prendergast Issued 2,650,000 $646,600
Issue of options. Black Scholes option
valuation methodology, estimated value
14 Nov 2024 Justin Ward Issued 1,000,000 $244,000
Issue of options. Black Scholes option
valuation methodology.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr James Hamilton Bray Graham Managing DirectorExecutive DirectorChief Executive Officer Jun 2015
Mr Graham has experience in marketing, business development and commercialisation of early-stage technologies with global potential.
Mr Alistair Gregory McKeough Non-Executive Director Nov 2017
Mr McKeough is an experienced executive and solicitor. He has experience serving as a director in many sectors, including for companies involved in professional services, corporate services, regulatory technology, sports technology, charities, health, biotech, childcare and education. He is the Chair of Risk Committee.
Dr Alan William Dunton Chief Medical AdvisorNon-Executive Director Jul 2020
Dr Dunton brings experience with over three decades in senior pharmaceutical roles. Notably, he served as the President and Managing Director of the Janssen Research Foundation (J&J Research). He is a member of Risk Committee.
Ms Michele Keryn Dilizia Chief Scientific OfficerExecutive Director Jun 2015
Ms Dilizia is a co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. She successfully co-led the research and development of Recce's suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).
Dr John Prendergast Executive ChairmanExecutive Director Apr 2018
Dr Prendergast is an executive in the pharmaceutical industry. Currently serving as the Chairman and Co-founder of Palatin Technologies, Inc. and the Lead Director of Nighthawk Biosciences (NYSE: HHWK), he brings over three decades of experience in the commercialisation of pharmaceutical technologies. He is a member of Risk Committee.
Dr Justin Leigh Ward Executive Director Jul 2019
Dr Ward is a qualified Chemist and Pharmacist with over 20 years of pharmaceutical and biotech industry experience in quality control, quality assurance, product research and development with leading pharmaceutical companies, including Pfizer. Dr Ward previously held a technical role with Pfizer, involving providing data for regulatory submissions to the FDA and TGA.
Ms Maggie Niewidok Company Secretary Sep 2022
-
Justin Reynolds Chief Financial Officer
-
Maggie Niewidok Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Graham John Hamilton Melrose & Ms Olga Mary Melrose 32,353,311 13.97%
HSBC Custody Nominees (Australia) Limited 14,970,467 6.46%
Buttonwood Nominees Pty Ltd 9,720,451 4.20%
Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss 7,700,000 3.32%
BNP Paribas Noms Pty Ltd 7,076,356 3.06%
Acuity Capital Investment Management Pty Ltd <Acuity Capital Holdings A/C> 4,500,000 1.94%
Acewood Investments Pty Ltd <Chivers Super Fund A/C> 3,537,101 1.53%
Pejay Pty Limited 3,300,000 1.42%
Mr John James Liddelow <John Liddelow A/C> 3,200,000 1.38%
BNP Paribas Nominees Pty Ltd <Clearstream> 2,986,111 1.29%
Ms Michele Keryn Dilizia 2,828,485 1.22%
Mr Arthur Nicholas Veliss & Mr Mark Anthony Rogers <Artmark Super Fund A/C> 2,500,000 1.08%
Mr Graham Melrose & Ms Olga Melrose 2,475,000 1.07%
J P Morgan Nominees Australia Pty Limited 2,177,007 0.94%
Querion Pty Ltd 2,100,000 0.91%
Seneschal (WA) Pty Ltd <Winston Scotney Family S A/C> 2,066,666 0.89%
Citicorp Nominees Pty Limited 1,964,710 0.85%
LDU Pty Ltd <Vesty Super Fund A/C> 1,933,219 0.83%
Haultrans Management Pty Limited <Successful Super Fund A/C> 1,870,000 0.81%
Mr John James Liddelow 1,605,000 0.69%

Profile

since

Note